CD8A and breast carcinoma: A phase II study in breast cancer patients supports this approach by showing an increase in lymphocytes and CD8+ T-cells in tumors exposed to single-agent denosumab (D-BEYOND; ClinicalTrials.gov Identifier: NCT01864798) [21].